Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026International ImmunopharmacologyOpen Access

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XGXin GaoCentral South UniversityJLJinhui LiuCentral South UniversityDDDingshan DengCentral South University

Discussion

Loading...

Member takes

Overview

Analyses uncover ZNF737 as a key driver of immune exclusion in bladder cancer, indicating its potential as a biomarker for therapy resistance.

Key Points

  • This research aims to investigate the role of ZNF737 in promoting immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
  • Conducted multi-omics analysis, including bulk and single-cell RNA sequencing.
  • Performed in vitro assays to assess the function of ZNF737 in cell migration, invasion, and T-cell chemotaxis.
  • Utilized multiplex immunofluorescence on tissue microarrays to establish clinical relevance.
  • Evaluated the therapeutic impact of ZNF737 depletion in a humanized mouse model.
  • ZNF737 was identified as a critical repressor of CXCL10, leading to reduced CD8+ T cell recruitment.
  • Depletion of ZNF737 shifted the tumor microenvironment from 'immune-desert' to an 'inflamed' state and sensitized tumors to anti-PD-1 therapy.
  • High ZNF737 expression correlated with resistance to immune checkpoint blockade across multiple clinical cohorts.

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/69abc0b85af8044f7a4e96b8https://doi.org/10.1016/j.intimp.2026.116443
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial2016 · 3,762 citations
  2. 2TIMER2.0 for analysis of tumor-infiltrating immune cells2020 · 5,803 citations
  3. 3SNAIL1: Linking Tumor Metastasis to Immune Evasion2021 · 97 citations
  4. 4Molecular subtype classification of urothelial carcinoma in Lynch syndrome2018 · 38 citations
  5. 5Cold Tumors: A Therapeutic Challenge for Immunotherapy2019 · 1,152 citations